Last reviewed · How we verify

high-grade B-cell lymphoma — Treatment Landscape & Competitive Intelligence

high-grade B-cell lymphoma (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating high-grade B-cell lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zynlonta LONCASTUXIMAB ADC Therapeutics SA 2022-01-01
Kymriah TISAGENLECLEUCEL Novartis Pharmaceuticals Corporation CD19-directed Chimeric Antigen Receptor [EPC] 2018-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. ADC Therapeutics SA · 1 drug in high-grade B-cell lymphoma
  2. Novartis Pharmaceuticals Corporation · 1 drug in high-grade B-cell lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in high-grade B-cell lymphoma:

Cite this brief

Drug Landscape (2026). high-grade B-cell lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/high-grade-b-cell-lymphoma. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing